# Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis

> **NCT07283887** · PHASE4 · RECRUITING · sponsor: **National Taiwan University Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Denosumab
- **DRUG:** Romosozumab

## Key facts

- **NCT ID:** NCT07283887
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07283887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07283887, "Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07283887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*